metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M) 1
limited stage SCLC (ls-SCLC) - 2nd Line (L2)
melanoma (ML)

All treatments
immune chekpoint inhibitors
Immune checkpoint association
nivolumab plus ipilimumab

versus all
vs non active control
vs no additional treatment

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open